Cargando…

Critical NIH Resources to Advance Therapies for Pain: Preclinical Screening Program and Phase II Human Clinical Trial Network

Opioid-related death and overdose have now reached epidemic proportions. In response to this public health crisis, the National Institutes of Health (NIH) launched the Helping to End Addiction Long-term Initiative(SM), or NIH HEAL Initiative(SM), an aggressive, trans-agency effort to speed scientifi...

Descripción completa

Detalles Bibliográficos
Autores principales: Iyengar, Smriti, Woller, Sarah A., Hommer, Rebecca, Beierlein, Jennifer, Wright, Clinton B., Tamiz, Amir P., Karp, Barbara I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7609631/
https://www.ncbi.nlm.nih.gov/pubmed/32876848
http://dx.doi.org/10.1007/s13311-020-00918-2
_version_ 1783605053103276032
author Iyengar, Smriti
Woller, Sarah A.
Hommer, Rebecca
Beierlein, Jennifer
Wright, Clinton B.
Tamiz, Amir P.
Karp, Barbara I.
author_facet Iyengar, Smriti
Woller, Sarah A.
Hommer, Rebecca
Beierlein, Jennifer
Wright, Clinton B.
Tamiz, Amir P.
Karp, Barbara I.
author_sort Iyengar, Smriti
collection PubMed
description Opioid-related death and overdose have now reached epidemic proportions. In response to this public health crisis, the National Institutes of Health (NIH) launched the Helping to End Addiction Long-term Initiative(SM), or NIH HEAL Initiative(SM), an aggressive, trans-agency effort to speed scientific solutions to stem the national opioid public health crisis. Herein, we describe two NIH HEAL Initiative programs to accelerate development of non-opioid, non-addictive pain treatments: The Preclinical Screening Platform for Pain (PSPP) and Early Phase Pain Investigation Clinical Network (EPPIC-Net). These resources are provided at no cost to investigators, whether in academia or industry and whether within the USA or internationally. Both programs consider small molecules, biologics, devices, and natural products for acute and chronic pain, including repurposed and combination drugs. Importantly, confidentiality and intellectual property are protected. The PSPP provides a rigorous platform to identify and profile non-opioid, non-addictive therapeutics for pain. Accepted assets are evaluated in in vitro functional assays to rule out opioid receptor activity and to assess abuse liability. In vivo pharmacokinetic studies measure plasma and brain exposure to guide the dose range and pretreatment times for the side effect profile, efficacy, and abuse liability. Studies are conducted in accordance with published rigor criteria. EPPIC-Net provides academic and industry investigators with expert infrastructure for phase II testing of pain therapeutics across populations and the lifespan. For assets accepted after a rigorous, objective scientific review process, EPPIC-Net provides clinical trial design, management, implementation, and analysis. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s13311-020-00918-2) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-7609631
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-76096312020-11-10 Critical NIH Resources to Advance Therapies for Pain: Preclinical Screening Program and Phase II Human Clinical Trial Network Iyengar, Smriti Woller, Sarah A. Hommer, Rebecca Beierlein, Jennifer Wright, Clinton B. Tamiz, Amir P. Karp, Barbara I. Neurotherapeutics Review Opioid-related death and overdose have now reached epidemic proportions. In response to this public health crisis, the National Institutes of Health (NIH) launched the Helping to End Addiction Long-term Initiative(SM), or NIH HEAL Initiative(SM), an aggressive, trans-agency effort to speed scientific solutions to stem the national opioid public health crisis. Herein, we describe two NIH HEAL Initiative programs to accelerate development of non-opioid, non-addictive pain treatments: The Preclinical Screening Platform for Pain (PSPP) and Early Phase Pain Investigation Clinical Network (EPPIC-Net). These resources are provided at no cost to investigators, whether in academia or industry and whether within the USA or internationally. Both programs consider small molecules, biologics, devices, and natural products for acute and chronic pain, including repurposed and combination drugs. Importantly, confidentiality and intellectual property are protected. The PSPP provides a rigorous platform to identify and profile non-opioid, non-addictive therapeutics for pain. Accepted assets are evaluated in in vitro functional assays to rule out opioid receptor activity and to assess abuse liability. In vivo pharmacokinetic studies measure plasma and brain exposure to guide the dose range and pretreatment times for the side effect profile, efficacy, and abuse liability. Studies are conducted in accordance with published rigor criteria. EPPIC-Net provides academic and industry investigators with expert infrastructure for phase II testing of pain therapeutics across populations and the lifespan. For assets accepted after a rigorous, objective scientific review process, EPPIC-Net provides clinical trial design, management, implementation, and analysis. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s13311-020-00918-2) contains supplementary material, which is available to authorized users. Springer International Publishing 2020-09-02 2020-07 /pmc/articles/PMC7609631/ /pubmed/32876848 http://dx.doi.org/10.1007/s13311-020-00918-2 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Review
Iyengar, Smriti
Woller, Sarah A.
Hommer, Rebecca
Beierlein, Jennifer
Wright, Clinton B.
Tamiz, Amir P.
Karp, Barbara I.
Critical NIH Resources to Advance Therapies for Pain: Preclinical Screening Program and Phase II Human Clinical Trial Network
title Critical NIH Resources to Advance Therapies for Pain: Preclinical Screening Program and Phase II Human Clinical Trial Network
title_full Critical NIH Resources to Advance Therapies for Pain: Preclinical Screening Program and Phase II Human Clinical Trial Network
title_fullStr Critical NIH Resources to Advance Therapies for Pain: Preclinical Screening Program and Phase II Human Clinical Trial Network
title_full_unstemmed Critical NIH Resources to Advance Therapies for Pain: Preclinical Screening Program and Phase II Human Clinical Trial Network
title_short Critical NIH Resources to Advance Therapies for Pain: Preclinical Screening Program and Phase II Human Clinical Trial Network
title_sort critical nih resources to advance therapies for pain: preclinical screening program and phase ii human clinical trial network
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7609631/
https://www.ncbi.nlm.nih.gov/pubmed/32876848
http://dx.doi.org/10.1007/s13311-020-00918-2
work_keys_str_mv AT iyengarsmriti criticalnihresourcestoadvancetherapiesforpainpreclinicalscreeningprogramandphaseiihumanclinicaltrialnetwork
AT wollersaraha criticalnihresourcestoadvancetherapiesforpainpreclinicalscreeningprogramandphaseiihumanclinicaltrialnetwork
AT hommerrebecca criticalnihresourcestoadvancetherapiesforpainpreclinicalscreeningprogramandphaseiihumanclinicaltrialnetwork
AT beierleinjennifer criticalnihresourcestoadvancetherapiesforpainpreclinicalscreeningprogramandphaseiihumanclinicaltrialnetwork
AT wrightclintonb criticalnihresourcestoadvancetherapiesforpainpreclinicalscreeningprogramandphaseiihumanclinicaltrialnetwork
AT tamizamirp criticalnihresourcestoadvancetherapiesforpainpreclinicalscreeningprogramandphaseiihumanclinicaltrialnetwork
AT karpbarbarai criticalnihresourcestoadvancetherapiesforpainpreclinicalscreeningprogramandphaseiihumanclinicaltrialnetwork